Caris Life Sciences (CAI) Common Equity (2024 - 2026)

Caris Life Sciences' Common Equity history runs 3 years deep, the most recent figure standing at $593.5 million for Q1 2026.

• In Q1 2026, Common Equity rose 122.83% year-over-year to $593.5 million; the TTM figure through Mar 2026 stood at $593.5 million (up 122.83% YoY), while the FY2025 annual figure was $577.3 million, up 123.1% from the prior year.
• Common Equity for Q1 2026 stood at $593.5 million, up from $577.3 million in the prior quarter.
• The five-year high for Common Equity was $593.5 million in Q1 2026, with the low at -$2.6 billion in Q1 2025.
• The 3-year median for Common Equity is -$953.3 million (2024), against an average of -$974.8 million.
• Peak annual rise in Common Equity reached 123.1% in 2025, while the deepest fall reached 119.19% in 2025.
• Caris Life Sciences' Common Equity stood at -$2.5 billion in 2024, then jumped by 123.1% to $577.3 million in 2025, then rose by 2.8% to $593.5 million in 2026.
• Business Quant data shows CAI's Common Equity at $593.5 million in Q1 2026, $577.3 million in Q4 2025, and $478.4 million in Q3 2025.